BACKGROUND: Thrombocytopenia and leukopenia are common complications of alcoholic liver cirrhosis (ALC) and are associated with an increased risk of bleeding, infection and mortality. OBJECTIVES: Evaluate the effectiveness and safety of leucogen, a cysteine derivative that increases platelet (PLT) and white blood cell (WBC) counts in ALC patients. DESIGN: Retrospective. SETTING: Department of hepatology, general hospital. PATIENTS AND METHODS: Patients with ALC who had thrombocytopenia and/or leukopenia were enrolled between 2022 and 2023 and were divided into two groups based on their treatment: the leucogen group (20 mg, three times per day) and the non-leucogen group. MAIN OUTCOME MEASURES: The primary endpoint was an increase in PLT or WBC of ≥5% from baseline. SAMPLE SIZE: 413 patients (320 patients in the final analysis). RESULTS: In this retrospective study, 320 patients were analyzed post-propensity score matching: 160 patients each in the leucogen and non-leucogen groups. Following 3 months of treatment, the leucogen group experienced a median increase in PLT levels of 1.0×10 CONCLUSIONS: Leucogen effectively increased PLT and WBC counts in patients with ALC, showing a favorable safety profile. LIMITATIONS: Retrospective study.